natr-20220630

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________________________________________________________

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File Number: 001-34483

NATURE’S SUNSHINE PRODUCTS, INC.

(Exact name of Registrant as specified in its charter)


Utah						87-0327982
(State or other jurisdiction of						(IRS Employer
incorporation or organization)						Identification No.)

2901 Bluegrass Boulevard, Suite 100

Lehi, Utah 84043

(Address of principal executive offices and zip code)

(801) 341-7900

(Registrant’s telephone number including area code)

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, no par value	NATR	Nasdaq Capital Market

Indicate by check mark whether the registrant; (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ý No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and an “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer o						Accelerated filer ☒

Non-accelerated filer o						Smaller reporting company ☒

						Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Table of Contents

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ý.

The number of shares of Common Stock, no par value, outstanding on July 22, 2022, was 19,224,999 shares.

Table of Contents

NATURE’S SUNSHINE PRODUCTS, INC.

FORM 10-Q

For the Quarter Ended June 30, 2022

Table of Contents


Part I. Financial Information			4

	Item 1.	Financial Statements (Unaudited)	4

		Condensed Consolidated Balance Sheets	4
		Condensed Consolidated Statements of Operations	5
		Condensed Consolidated Statements of Comprehensive Incom e (loss)	7
		Condensed Consolidated Statement s of Changes in Shareholders’ Equity	8
		Condensed Consolidated Statements of Cash Flows	9
		Notes to Condensed Consolidated Financial Statements	10

	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	22

	Item 3.	Quantitative and Qualitative Disclosures about Market Risk	31

	Item 4.	Controls and Procedures	31

Part II. Other Information			32

	Item 1.	Legal Proceedings	32

	Item 1A.	Risk Factors	32

	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	33

	Item 3.	Defaults Upon Senior Securities	33

	Item 4.	Mine Safety Disclosures	33

	Item 5.	Other Information	33

	Item 6.	Exhibits	34

Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain information included or incorporated herein by reference in this report may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies. All statements (other than statements of historical fact) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made in light of our experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate. For example, information appearing under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” includes forward-looking statements. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are more fully described in this report, including the risks set forth under “Risk Factors” in Item 1A, and in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, but include the following:

•extensive government regulations to which the Company’s products, business practices and manufacturing activities are subject;

•registration of products for sale in foreign markets, or difficulty or increased cost of importing products into foreign markets;

•legal challenges to the Company’s direct selling program or to the classification of its independent consultants;

•laws and regulations regarding direct selling may prohibit or restrict our ability to sell our products in some markets or require us to make changes to our business model in some markets;

•liabilities and obligations arising from improper activity by the Company’s independent consultants;

•product liability claims;

•impact of anti-bribery laws, including the U.S. Foreign Corrupt Practices Act;

•the Company’s ability to attract and retain independent consultants;

•the loss of one or more key independent consultants who have a significant sales network;

•the Company’s joint venture for operations in China with Fosun Industrial Co., Ltd.;

•the effect of fluctuating foreign exchange rates;

•failure of the Company’s independent consultants to comply with advertising laws;

•changes to the Company’s independent consultants compensation plans;

•geopolitical issues and conflicts;

•adverse effects caused by the ongoing coronavirus pandemic;

•negative consequences resulting from difficult economic conditions, including the availability of liquidity or the willingness of the Company’s customers to purchase products;

•risks associated with the manufacturing of the Company’s products;

•supply chain disruptions, manufacturing interruptions or delays, or the failure to accurately forecast customer demand;

•failure to timely and effectively obtain shipments of products from our manufacturers and deliver products to our independent consultants and customers;

•world-wide slowdowns and delays related to supply chain, ingredient shortages and logistical challenges;

•uncertainties relating to the application of transfer pricing, duties, value-added taxes, and other tax regulations, and changes thereto;

•changes in tax laws, treaties or regulations, or their interpretation;

•cybersecurity threats and exposure to data loss;

•the storage, processing, and use of data, some of which contain personal information, are subject to complex and evolving privacy and data protection laws and regulations;

•reliance on information technology infrastructure; and

•the sufficiency of trademarks and other intellectual property rights.

All forward-looking statements speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this report. Except as is required by law, we expressly disclaim any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this report. Throughout this report, we refer to Nature’s Sunshine Products, Inc., together with our subsidiaries, as "we," "us," "our," "our Company" or “the Company.”

Table of Contents

PART I FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS

NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands)

(Unaudited)


	June 30, 2022		December 31, 2021
Assets
Current assets:
Cash and cash equivalents	$	56,344	$	86,184
Accounts receivable, net of allowance for doubtful accounts of $525 and $143, respectively	10,540		8,871


Inventories	70,643		60,852
Prepaid expenses and other	9,618		8,760
Total current assets	147,145		164,667

Property, plant and equipment, net	49,099		50,857
Operating lease right-of-use assets	18,060		18,349
Investment securities - trading	743		964

Deferred income tax assets	7,794		13,590
Other assets	10,218		10,447
Total assets	$	233,059	$	258,874

Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable	$	9,423	$	9,702
Accrued volume incentives and service fees	23,199		23,131
Accrued liabilities	26,842		31,600
Deferred revenue	1,829		3,694

Related party notes payable	—		302
Income taxes payable	2,227		2,647
Current portion of operating lease liabilities	4,336		4,350
Current portion of note payable	1,263		1,244
Total current liabilities	69,119		76,670


Long-term portion of operating lease liabilities	15,871		15,919

Long-term note payable	537		1,174
Deferred compensation payable	743		964
Deferred income tax liabilities	1,212		1,566
Other liabilities	1,098		1,177
Total liabilities	88,580		97,470



Shareholders’ equity:
Common stock, no par value, 50,000 shares authorized, 19,259 and 19,724 shares issued and outstanding, respectively	121,623		133,382
Retained earnings	32,591		35,025
Noncontrolling interest	3,902		3,202
Accumulated other comprehensive loss	(13,637)		(10,205)
Total shareholders’ equity	144,479		161,404
Total liabilities and shareholders’ equity	$	233,059	$	258,874

See accompanying notes to condensed consolidated financial statements.

Table of Contents

NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Amounts in thousands, except per share information)

(Unaudited)


	Three Months Ended June 30,
	2022		2021
Net sales	$	104,161	$	108,978
Cost of sales	29,471		28,463
Gross profit	74,690		80,515

Operating expenses:
Volume incentives	32,069		35,443
Selling, general and administrative	36,866		35,586
Operating income	5,755		9,486
Other income (loss), net	(442)		529
Income before provision for income taxes	5,313		10,015
Provision for income taxes	4,361		3,221
Net income	952		6,794
Net income attributable to noncontrolling interests	436		254
Net income attributable to common shareholders	$	516	$	6,540

Basic and diluted net income per common share:




Basic earnings per share attributable to common shareholders	$	0.03	$	0.33




Diluted earnings per share attributable to common shareholders	$	0.03	$	0.32

Weighted average basic common shares outstanding	19,386		19,999
Weighted average diluted common shares outstanding	19,594		20,503

See accompanying notes to condensed consolidated financial statements.

Table of Contents

NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except per share information)

(Unaudited)


	Six Months Ended June 30,
	2022		2021
Net sales	$	214,655	$	211,399
Cost of sales	63,931		55,442
Gross profit	150,724		155,957

Operating expenses:
Volume incentives	66,171		69,698
Selling, general and administrative	77,489		69,138
Operating income	7,064		17,121
Other loss, net	(756)		(1,404)
Income before provision for income taxes	6,308		15,717
Provision for income taxes	8,042		4,771
Net income (loss)	(1,734)		10,946
Net income attributable to noncontrolling interests	700		390
Net income (loss) attributable to common shareholders	$	(2,434)	$	10,556

Basic and diluted net income per common share:




Basic earnings (loss) per share attributable to common shareholders	$	(0.12)	$	0.53




Diluted earnings (loss) per share attributable to common shareholders	$	(0.12)	$	0.52

Weighted average basic common shares outstanding	19,479		19,897
Weighted average diluted common shares outstanding	19,479		20,340

Dividends declared per common share	$	—	$	1.00

See accompanying notes to condensed consolidated financial statements.

Table of Contents

NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Amounts in thousands)

(Unaudited)


	Three Months Ended June 30,
	2022		2021
Net income	$	952	$	6,794
Foreign currency translation loss (net of tax)	(2,457)		(45)



Total comprehensive income (loss)	$	(1,505)	$	6,749


	Six Months Ended June 30,
	2022		2021
Net income (loss)	$	(1,734)	$	10,946
Foreign currency translation loss (net of tax)	(3,432)		(166)


Total comprehensive income (loss)	$	(5,166)	$	10,780

See accompanying notes to condensed consolidated financial statements.

Table of Contents

NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(Amounts in thousands)

(Unaudited)


	Common Stock			Retained Earnings		Noncontrolling Interest		Accumulated Other Comprehensive Loss		Total
	Shares	Amount
Balance at December 31, 2021	19,724	$	133,382	$	35,025	$	3,202	$	(10,205)	$	161,404
Share-based compensation expense	—	801		—		—		—		801
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax	218	(795)		—		—		—		(795)
Repurchase of common stock	(451)	(7,971)		—		—		—		(7,971)
Net income (loss)	—	—		(2,950)		264		—		(2,686)
Other comprehensive loss	—	—		—		—		(975)		(975)
Balance at March 31, 2022	19,491	$	125,417	$	32,075	$	3,466	$	(11,180)	$	149,778
Share-based compensation expense	—	540		—		—		—		540
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax	58	(334)		—		—		—		(334)
Repurchase of common stock	(290)	(4,000)		—		—		—		(4,000)
Net income	—	—		516		436		—		952
Other comprehensive loss	—	—		—		—		(2,457)		(2,457)
Balance at June 30, 2022	19,259	$	121,623	$	32,591	$	3,902	$	(13,637)	$	144,479


	Common Stock			Retained Earnings		Noncontrolling Interest		Accumulated Other Comprehensive Loss		Total
	Shares	Amount
Balance at December 31, 2020	19,697	$	139,311	$	26,030	$	1,848	$	(9,955)	$	157,234
Share-based compensation expense	—	1,005		—		—		—		1,005
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax	218	(914)		—		—		—		(914)
Cash dividends ($1.00 per share)	—	—		(19,858)		—		—		(19,858)
Net income	—	—		4,016		136		—		4,152
Other comprehensive loss	—	—		—		—		(121)		(121)
Balance at March 31, 2021	19,915	$	139,402	$	10,188	$	1,984	$	(10,076)	$	141,498
Share-based compensation expense	—	1,066		—		—		—		1,066
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax	152	(660)		—		—		—		(660)
Repurchase of common stock	(77)	(1,500)		—		—		—		(1,500)
Net income	—	—		6,540		254		—		6,794
Other comprehensive loss	—	—		—		—		(45)		(45)
Balance at June 30, 2021	19,990	$	138,308	$	16,728	$	2,238	$	(10,121)	$	147,153

See accompanying notes to condensed consolidated financial statements.

Table of Contents

NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in thousands)

(Unaudited)


	Six Months Ended June 30,
	2022		2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$	(1,734)	$	10,946
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Provision for doubtful accounts	417		—
Depreciation and amortization	5,451		5,541
Non-cash lease expense	2,785		2,626
Share-based compensation expense	1,341		2,071
Loss on sale of property, plant and equipment	—		12
Deferred income taxes	5,338		1,753
Purchase of trading investment securities	(19)		(24)
Proceeds from sale of trading investment securities	69		175
Realized and unrealized gains (losses) on investments	170		(67)
Foreign exchange losses	803		1,572
Changes in assets and liabilities:
Accounts receivable	(2,801)		(2,755)
Inventories	(11,910)		(3,777)
Prepaid expenses and other current assets	(1,357)		(918)
Other assets	(33)		(108)
Accounts payable	(80)		1,079
Accrued volume incentives and service fees	1,045		483
Accrued liabilities	(4,001)		(5,473)
Deferred revenue	(1,718)		(111)
Lease liabilities	(2,503)		(2,487)
Income taxes payable	(386)		261
Liability related to unrecognized tax benefits	—		(87)
Deferred compensation payable	(220)		—
Net cash provided by (used in) operating activities	(9,343)		10,712
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment	(3,757)		(2,898)



Net cash used in investing activities	(3,757)		(2,898)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of cash dividends	—		(19,858)
Principal payments of long-term debt	(618)		(698)
Proceeds from revolving credit facility	15,645		—
Principal payments of revolving credit facility	(15,645)		—

Principal payments of related party borrowing	(300)		—

Payments related to tax withholding for net-share settled equity awards	(1,129)		(1,574)

Repurchase of common stock	(11,971)		(1,500)
Net cash used in financing activities	(14,018)		(23,630)
Effect of exchange rates on cash and cash equivalents	(2,722)		(1,351)
Net decrease in cash and cash equivalents	(29,840)		(17,167)
Cash and cash equivalents at the beginning of the period	86,184		92,069
Cash and cash equivalents at the end of the period	$	56,344	$	74,902
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes, net of refunds	$	4,173	$	2,582
Cash paid for interest	113		111

See accompanying notes to condensed consolidated financial statements.

Table of Contents

NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(1) Basis of Presentation

We are a natural health and wellness company primarily engaged in the manufacture and sale of nutritional and personal care products. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products directly to customers and to a sales force of independent consultants who use the products themselves or resell them to consumers.

Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of our financial information as of June 30, 2022, and for the three and six-month periods ended June 30, 2022 and 2021. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2022.

These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021.

Use of Estimates

The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities, in these financial statements and accompanying notes. Actual results could differ from these estimates due to the uncertainty around the magnitude and duration of the COVID-19 pandemic, as well as other factors, and those differences could have a material effect on our financial position and results of operations.

The significant accounting estimates inherent in the preparation of our financial statements include estimates associated with our determination of liabilities related to independent consultant incentives, the determination of income tax assets and liabilities, certain other non-income tax and value-added tax contingencies, and legal contingencies. In addition, significant estimates form the basis for allowances with respect to inventory valuations. Various assumptions and other factors enter into the determination of these significant estimates. The process of determining significant estimates takes into account historical experience and current and expected economic conditions.

Noncontrolling Interests

Noncontrolling interests changed as a result of the net income attributable to noncontrolling interests of $0.4 million and $0.7 million for the three and six months ended June 30, 2022, respectively. Net income attributable to the noncontrolling interests was $0.3 million and $0.4 million for the three and six months ended June 30, 2021, respectively. As of June 30, 2022 and December 31, 2021, noncontrolling interests were $3.9 million and $3.2 million, respectively.

Restructuring Related Accruals and Expenses

We recorded $0 and $0.3 million of restructuring related expenses during the three and six months ended June 30, 2022, respectively. We recorded $0 and $48,000 of restructuring related expenses during the three and six months ended June 30, 2021, respectively. Accrued severance and restructuring related costs were $5,000 and $0.2 million as of June 30, 2022 and December 31, 2021, respectively.

Recent Accounting Pronouncements

In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides optional guidance for a limited period of time to ease the

Table of Contents

potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments in this update are elective and subject to meeting certain criteria, that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This could affect balances of right of use assets, lease liabilities, and notes payables. The amendments in this update are effective as of March 12, 2020 through December 21, 2022. The adoption of this ASU is not expected to have a significant impact on our Consolidated Financial Statements.

(2) Inventories

The composition of inventories is as follows (dollar amounts in thousands):


	June 30, 2022		December 31, 2021
Raw materials	$	27,680	$	22,494
Work in progress	1,930		1,746
Finished goods	41,033		36,612
Total inventories	$	70,643	$	60,852

(3) Investment Securities - Trading

Our trading securities portfolio totaled $0.7 million at June 30, 2022, and $1.0 million at December 31, 2021, and generated losses of $0.1 million and gains of $0.1 million for the three months ended June 30, 2022 and 2021, respectively, and losses of $0.2 million and gains of $0.1 million for the six months ended June 30, 2022 and 2021, respectively.

(4) Revolving Credit Facility and Other Obligations

On July 11, 2017, we entered into a revolving credit agreement with Bank of America, N.A., with a borrowing limit of $25.0 million (the “Credit Agreement”). On June 23, 2022 the credit agreement was amended to extend the term to mature on July 1, 2027 and allows for additional borrowings of $25.0 million or up to three separate increases of no less than $5.0 million each. The amendment to the credit agreement also modified the calculation of interest. Interest under the amended Credit Agreement is the greater of BSBY Daily Floating Rate or the Index Floor, plus 1.50 percent (3.10 percent as of June 30, 2022), and an annual commitment fee of 0.25 percent on the unused portion of the commitment. At June 30, 2022 and December 31, 2021, there was no outstanding balance under the Credit Agreement.

The Credit Agreement contains customary financial covenants, including financial covenants relating to our solvency and leverage. In addition, the Credit Agreement restricts certain capital expenditures, lease expenditures, other indebtedness, liens on assets, guarantees, loans and advances, dividends, mergers, consolidations and transfers of assets except as permitted in the Credit Agreement. The Credit Agreement is collateralized by our manufacturing facility, accounts receivable, inventories and other assets. As of June 30, 2022, we were in compliance with the debt covenants set forth in the Credit Agreement.

On April 21, 2020, we entered into a credit agreement with Banc of America Leasing and Capital, LLC, with a borrowing limit of $6.0 million (the "Capital Credit Agreement"). On November 19, 2020, we executed on the Capital Credit Agreement and borrowed $3.7 million. We pay interest on any borrowings under the Capital Credit Agreement at a fixed rate of 3.00 percent and are required to settle our borrowings under the Capital Credit Agreement in 36 monthly payments, of $0.1 million. The Capital Credit Agreement is collateralized by any new equipment purchased under the agreement. As of June 30, 2022, there was $1.8 million outstanding balance under the Capital Credit Agreement, of which $1.3 million was classified as current.

(5) Net Income Per Share

Basic net income per common share (“Basic EPS”), is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share (“Diluted EPS”) reflects the potential dilution that could occur if stock options or other contracts to issue common stock were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share.

Table of Contents

Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three and six months ended June 30, 2022 and 2021 (dollar and share amounts in thousands, except for per share information):


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022			2021



Net income (loss) attributable to common shareholders	$	516	$	6,540	$	(2,434)		$	10,556

Basic weighted average shares outstanding	19,386		19,999		19,479			19,897




Basic earnings (loss) per share attributable to common shareholders	$	0.03	$	0.33	$	(0.12)		$	0.53

Diluted shares outstanding:
Basic weighted-average shares outstanding	19,386		19,999		19,479			19,897
Stock-based awards	208		504		—			443
Diluted weighted-average shares outstanding	19,594		20,503		19,479			20,340




Diluted earnings (loss) per share attributable to common shareholders	$	0.03	$	0.32	$	(0.12)		$	0.52

Dilutive shares excluded from diluted-per-share amounts:
Stock options	341		563		—			563

Anti-dilutive shares excluded from diluted-per-share amounts:
Stock options	25		—		341		(1)	—

_________________________________________

(1) As a result of the net loss for the six months ended June 30, 2022, no potentially dilutive securities are included in the calculation of diluted loss per share because such effect would be anti-dilutive. Potentially dilutive securities for the six months ended June 30, 2022 include 341 restricted stock units.

Potentially dilutive shares excluded from diluted-per-share amounts include performance-based options to purchase shares of common stock for which certain earnings metrics have not been achieved. Potentially anti-dilutive shares excluded from diluted-per-share amounts include both non-qualified stock options and unearned performance-based options to purchase shares of common stock with exercise prices greater than the weighted- average share price during the period and shares that would be anti-dilutive to the computation of diluted net income per share for each of the periods presented.

(6) Capital Transactions

Dividends

On March 10, 2021, we announced a special non-recurring cash dividend of $1.00 per common share in an aggregate amount of $19.9 million that was paid on April 5, 2021, to shareholders of record on March 29, 2021. In accordance with the provisions of our 2012 Stock Incentive Plan (the "2012 Incentive Plan"), as a result of the special dividend we are required to make the participant's original grant whole by preventing either dilution or enlargement of the benefits or potential benefits intended by the original grant. The 2012 Incentive Plan provides our Compensation Committee with the discretion to meet this requirement. See further discussion in the Share-Based Compensation section of this Note.

The declaration of future dividends is subject to the discretion of our Board of Directors and will depend upon various factors, including our earnings, financial condition, restrictions imposed by any indebtedness that may be outstanding, cash requirements, future prospects and other factors deemed relevant by our Board of Directors.

Table of Contents

Share Repurchase Program

On March 10, 2021, we announced a $15.0 million common share repurchase program. On March 8, 2022 we announced an amendment to the share repurchase program allowing the repurchase of an additional $30.0 million in common shares. The repurchases may be made from time to time as market conditions warrant and are subject to regulatory considerations. For the six months ended June 30, 2022 and 2021, we repurchased 741,000 and 77,000 shares of our common stock for $12.0 million and $1.5 million, respectively. At June 30, 2022, the remaining balance available for repurchases under the program was $25.6 million.

Share-Based Compensation

During the year ended December 31, 2012, our shareholders adopted and approved the Nature’s Sunshine Products, Inc. 2012 Stock Incentive Plan. The 2012 Incentive Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. The Compensation Committee of the Board of Directors has authority and discretion to determine the type of award, as well as the amount, terms and conditions of each award under the 2012 Incentive Plan, subject to the limitations of the 2012 Incentive Plan. A total of 1,500,000 shares of our common stock were originally authorized for the granting of awards under the 2012 Incentive Plan. In 2015, our shareholders approved an amendment to the 2012 Incentive Plan, to increase the number of shares of common stock reserved for issuance by 1,500,000 shares. On May 5, 2021, our shareholders approved the Amended and Restated 2012 Stock Incentive Plan, which among other amendments, increased the number of shares of common stock reserved for issuance by 2,000,000 shares. The number of shares available for awards, as well as the terms of outstanding awards, are subject to adjustment as provided in the Amended and Restated 2012 Incentive Plan for stock splits, stock dividends, recapitalizations and other similar events.

Stock Options

Our outstanding stock options include time-based stock options, which vest over differing periods of time ranging from the date of issuance to up to 48 months from the option grant date, and performance-based stock options, which have already vested upon achieving operating income margins of six, eight and ten percent as reported in four of five consecutive quarters over the term of the options.

Stock option activity for the six-month period ended June 30, 2022, is as follows (amounts in thousands, except per share information):


	Number of Shares	Weighted Average Exercise Price Per Share		Weighted Average Grant Date Fair Value
Options outstanding at December 31, 2021	172	$	12.13	$	5.05
Granted	—	—		—
Forfeited or canceled	—	—		—
Exercised	(29)	9.17		3.92
Options outstanding at June 30, 2022	143	$	12.72	$	5.28

There was no share-based compensation expense for the three- and six-month periods ended June 30, 2022 and 2021. As of June 30, 2022 and December 31, 2021, there was no unrecognized share-based compensation expense related to the grants described above.

At June 30, 2022, the aggregate intrinsic value of outstanding and exercisable stock options to purchase 143,000 shares of common stock was $41,000. At December 31, 2021, the aggregate intrinsic value of outstanding and exercisable options to purchase 172,000 shares of common stock was $1.1 million.

For the six-month periods ended June 30, 2022 and 2021, we issued 29,000 and 50,000 shares of common stock upon the exercise of stock options at an average exercise price of $9.17 and $12.00 per share, respectively. The aggregate intrinsic value of options exercised during the six-month periods ended June 30, 2022 and 2021, was $0.3 million and $0.4 million, respectively. For the six-month periods ended June 30, 2022 and 2021, the Company recognized $0.1 million and $0.2 million of tax benefits from the exercise of stock options, respectively.

As of June 30, 2022 and December 31, 2021, we did not have any unvested performance-based stock options outstanding.

Table of Contents

Restricted Stock Units

Our outstanding restricted stock units (“RSUs”), include time-based RSUs, which vest over differing periods of time ranging from 12 months to up to 36 months from the RSU grant date, as well as performance-based RSUs, which vest upon achieving targets relating to revenue and earnings growth, earnings-per-share, and/or stock price levels. RSUs granted to members of the Board of Directors contain a restriction period in which the shares are not issued until two years after vesting. At June 30, 2022 and December 31, 2021, there were 68,000 and 88,000 vested RSUs, respectively, granted to the Board of Directors with an accompanying restriction period.

Restricted stock unit activity for the six-month period ended June 30, 2022, is as follows (amounts in thousands, except per share information):


	Number of Shares	Weighted Average Grant Date Fair Value
Restricted Stock Units outstanding at December 31, 2021	830	$	9.46
Granted	164	8.87
Forfeited	(68)	5.39
Issued	(329)	7.50
Restricted Stock Units outstanding at June 30, 2022	597	10.84

During the six-month period ended June 30, 2022, we granted 164,000 RSUs under the 2012 Incentive Plan to the Board of Directors, executive officers and other employees, which were comprised of both time-based RSUs and share-priced performance-based RSUs. The time-based RSUs were issued with a weighted-average grant date fair value of $13.87 per share and vest in annual installments over a three-year period from the grant date. The share-priced performance-based RSUs were issued with a weighted-average grant date fair value of $6.01 per share and vest upon achieving share-priced targets over a three-year period from the grant date.

Except for share-priced performance RSUs, RSUs are valued at market value on the date of grant, which is the grant date share price discounted for expected dividend payments during the vesting period. For RSUs with post-vesting restrictions, a Finnerty Model was utilized to calculate a valuation discount from the market value of common shares reflecting the restriction embedded in the RSUs preventing the sale of the underlying shares over a certain period of time. Using assumptions previously determined for the application of the option pricing model at the valuation date, the Finnerty Model discount for lack of marketability is approximately 12.9 percent for a common share.

Share-price performance-based RSUs were estimated using the Monte Carlo simulation model. The Monte Carlo simulation model utilizes multiple input variables to estimate the probability that market conditions will be achieved. Our assumptions include a performance period of three years, expected volatility of 50.1 percent, and a risk-free rate of 3.3 percent.

Share-based compensation expense related to time-based RSUs for the three-month periods ended June 30, 2022 and 2021, was approximately $0.3 million and $0.6 million, respectively. Share-based compensation expense related to time-based RSUs for the six-month periods ended June 30, 2022 and 2021, was approximately $0.9 million and $1.0 million, respectively. As of June 30, 2022 and December 31, 2021, the unrecognized share-based compensation expense related to the grants described above, excluding incentive awards discussed below, was $1.4 million and $1.6 million, respectively. The remaining compensation expense is expected to be recognized over the weighted average period of approximately 0.3 years.

Share-based compensation expense related to performance-based RSUs for the three-month periods ended June 30, 2022 and 2021, was $0.2 million and $0.5 million, respectively. Share-based compensation expense related to performance-based RSUs for the six-month periods ended June 30, 2022 and 2021, was $0.5 million and $0.9 million, respectively. Should we attain all of the metrics related to performance-based RSU grants, we would, and expect to, recognize up to $2.4 million of potential share-based compensation expense.

The number of shares issued upon vesting of RSUs granted pursuant to our share-based compensation plans is net of the minimum statutory withholding requirements that we pay on behalf of our employees, which was 80,000 and 121,000 shares for the six-month periods ended June 30, 2022 and 2021, respectively. Although shares withheld are not issued, they are treated as common share repurchases for accounting purposes, as they reduce the number of shares that would have been issued upon vesting. These shares do not count against the authorized capacity under the repurchase program described above.

Table of Contents

(7) Segment Information

We have four business segments (Asia, Europe, North America, and Latin America and Other) based primarily upon the geographic region where each segment operates, as well as the internal organization of our officers and their responsibilities. Each of the geographic segments operate under the Nature’s Sunshine Products and Synergy WorldWide® brands. The Latin America and Other segment includes our wholesale business in which we sell products to various locally-managed entities independent of the Company that we have granted distribution rights for the relevant market.

Net sales for each segment have been reduced by intercompany sales as they are not included in the measure of segment profit or loss reviewed by the chief executive officer. We evaluate performance based on contribution margin by segment before consideration of certain inter-segment transfers and expenses.

Reportable business segment information is as follows (dollar amounts in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Net sales:
Asia	$	47,382	$	43,536	$	93,492	$	79,291
Europe	17,099		21,455		38,876		43,655
North America	34,082		37,372		70,063		75,134
Latin America and Other	5,598		6,615		12,224		13,319
Total net sales	104,161		108,978		214,655		211,399

Contribution margin (1):
Asia	21,432		18,463		43,371		33,782
Europe	6,595		6,588		10,968		13,384
North America	12,300		16,259		25,019		31,699
Latin America and Other	2,294		3,762		5,195		7,394
Total contribution margin	42,621		45,072		84,553		86,259

Selling, general and administrative expenses (2)	36,866		35,586		77,489		69,138
Operating income	5,755		9,486		7,064		17,121

Other income (loss), net	(442)		529		(756)		(1,404)
Income before provision for income taxes	$	5,313	$	10,015	$	6,308	$	15,717

_________________________________________

(1) Contribution margin consists of net sales less cost of sales and volume incentives expense.

(2) Service fees in China totaled $3.9 million and $8.8 million for the three and six-month periods ended June 30, 2022, respectively, compared to $3.7 million and $6.5 million for the three and six-month periods ended June 30, 2021. These service fees are included in selling, general and administrative expenses.

Table of Contents

From an individual country/region perspective, the United States, South Korea and Taiwan comprise 10 percent or more of consolidated net sales for the three and six-month periods ended June 30, 2022 and 2021, as follows (dollar amounts in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Net sales:
United States	$	31,483	$	34,378	$	64,712	$	69,298
South Korea	14,465		17,546		28,118		32,355
Taiwan	11,933		4,730		21,683		7,499
Other	46,280		52,324		100,142		102,247
	$	104,161	$	108,978	$	214,655	$	211,399

Table of Contents

Net sales generated by each of our product lines is set forth below (dollar amounts in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Asia
General health	$	12,319	$	12,698	$	25,305	$	23,990
Immune	781		382		2,125		585
Cardiovascular	13,242		12,260		26,872		22,163
Digestive	10,990		7,747		20,026		14,618
Personal care	2,083		5,290		4,626		7,814
Weight management	7,967		5,159		14,538		10,121
	47,382		43,536		93,492		79,291
Europe
General health	$	7,328	$	9,667	$	16,524	$	19,139
Immune	1,443		1,818		4,074		3,834
Cardiovascular	2,150		2,836		4,783		5,828
Digestive	4,481		5,567		10,072		11,107
Personal care	1,209